Middle ear abnormalities at age 5 years in relation with early onset otitis media and number of episodes, in the Inuit population of Nunavik, Quebec, Canada

P De Wals, J B Lemeur, H Ayukawa, J F Proulx, P De Wals, J B Lemeur, H Ayukawa, J F Proulx

Abstract

Otitis media (OM) and their sequelae are a major health issue in the Inuit population of Nunavik, Quebec. Hypotheses of the study were: (i) early onset OM leads to repeated OM; (ii) repeated OM episodes leads to middle ear abnormalities (MEA) at age 5 years, (iii) pneumococcal conjugate vaccines (PCVs) may reduce multiple OM and MEA. Immunisation cards, medical records and audiology screening tests at age 5 years in a sample of 610 children born in 1994-2010 in 3 communities were reviewed. Children were classified into three categories using a score based on audiology screening tests: no abnormality, minor, or major MEA. The average number of OM episodes before age 5 years was 5.0 and 30% had minor and 17% major MEA at age 5 years. Community residency predicted both frequent (≥ 8) OM episodes and MEA. Early onset OM (age <6 months) was a predictor of frequent OM (RR = 1.71; 95%CI: 1.50-1.95) whereas PCV (≥1 dose ≥ age 2 months) has no significant effect. Frequent OM episodes were associated with major MEA (RR = 2.16; 95%CI: 1.20-3.85). Although associations were not statistically significant, there was a trend towards a protective effect of PCV administration on frequent OM and minor MEA, but not major MEA. In conclusion, results support an association between early onset OM, frequent OM and MEA that could represent a causal pathway.

Trial registration: ClinicalTrials.gov NCT01694329.

Keywords: Inuit; Otitis media; Pneumococcal conjugate vaccines; audiology deficit.

Conflict of interest statement

Philippe De Wals received research grants and reimbursements of travel expenses from vaccine manufacturers including the GSK group of companies, Novartis, Pfizer and Sanofi Pasteur.

References

    1. MacMillan HI, MacMillan AB, Offord DR, et al. Aboriginal health. CAMJ. 1996;155:1569–6.
    1. Cléophat JE, Le Meur JB, Proulx JF, et al. Uptake of pneumococcal vaccines in the nordic region of Nunavik, province of Quebec, Canada. Can J Public Health. 2014;105:e268–e72.
    1. Le Meur JB, Ayukawa H, Proulx JF, et al. Prevalence of middle ear abnormalities from otitis media in relation with pneumococcal vaccine use in the Inuit population of Nunavik, province of Quebec, Canada. Vaccine. 2018;36:5180–5186. Epub 2018 Jul 17.
    1. Kvaerner KJ, Nafstad P, Hagen JA, et al. Recurrent acute otitis media: the significance of age at onset. Acta Otolaryngol. 1997;117:578–584.
    1. Todberg T, Koch A, Andersson Met al. Incidence of otitis media in a contemporary Danish National Birth Cohort. PLoS One. 2014;9:e111732 eCollection 2014.
    1. Boisvert I. Elaboration of a classification and score system for audiology screening data in Inuit children of Nunavik [Master’s thesis]. Department of Speech Therapy and Audiology, University of Montreal, 2004.
    1. Jervis-Bardy J, Sanchez L, Carney AS.. Otitis media in indigenous Australian children: review of epidemiology and risk factors. J Laryngol Otol. 2014;128(Suppl 1):S16–27.
    1. Gould JM, Matz PS.. Otitis media. Pediatr Rev. 2010;31:102–116.
    1. Zhang Y, Xu M, Zhang J, et al. Risk factors for chronic and recurrent otitis media-a meta-analysis. PLoS One. 2014;9:e86397 eCollection 2014.
    1. Vanderweele TJ. On the distinction between interaction and effect modification. Epidemiology. 2009;20:863–871.
    1. Vanderweele TJ. Invited commentary: structural equation models and epidemiologic analysis. Am J Epidemiol. 2012;176:608–612.
    1. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488–495.
    1. Dagan R, Pelton S, Bakaletz L. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16:480–492.
    1. Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003;361(9376):2189–2195.
    1. Leach AJ, Mulholland EK, Santosham M, et al. Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial. BMJ Open. 2015;5:e007247.
    1. O’Connor TE, Perry CF, Lannigan FJ. Complications of otitis media in indigenous and non-indigenous children. Med J Aust. 2009;19:S60–4.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다